Scholl Hendrik Peter 4

What Happened

• Hendrik Peter Scholl, Chief Medical Officer of Belite Bio, had 10,000 ordinary shares acquired on 04/21/2026 via the vesting of a previously granted option. The Form 4 reports the acquisition as a derivative transaction at $0.00 per share (total reported value $0).

Key Details

• Transaction date: 2026-04-21; Form 4 filed: 2026-04-23 (timely filing).
• Transaction type/code: Other acquisition/disposition (J) — derivative shares acquired through vesting.
• Price reported: $0.00 per share; total reported cash value $0.
• Footnote: Option was granted on 10/07/2025 and vested as to 10,000 shares when performance criteria were met on 04/21/2026.
• Shares owned after the transaction: Not specified in the filing.
• No simultaneous sale reported (shares were acquired, not sold).

Context

• This was a vesting of a previously granted option tied to performance goals, not an open-market purchase or sale. The filing indicates the insider received shares as the performance condition was satisfied; it does not show any immediate cashless exercise sale or disposition. Such vesting events are routine components of executive compensation and do not, by themselves, indicate a buy or sell decision by the insider.